In August 1949, a Chicago electronics tinkerer named Wallace H. Coulter filed a patent that looked almost trivially simple. A tube. A tiny hole. Two electrodes. Salty water on both sides. Push a fluid through the hole and watch the electrical resistance twitch. That was it.

The patent — US 2,656,508, "Means for Counting Particles Suspended in a Fluid", granted October 20, 1953 — is one of the most consequential biomedical patents of the 20th century, and almost nobody outside laboratory medicine has heard of it.

What it does. Suspend cells (or any particles) in a conductive electrolyte. Draw the suspension through a microscopic aperture between two chambers. Each time a non-conductive particle squeezes through, it briefly displaces its own volume of electrolyte inside the aperture. The resistance between the electrodes jumps. Count the pulses: you have the particle count. Measure the pulse height: you have each particle's volume, one at a time, thousands per second.

Who filed it. Coulter (b. 1913) dropped out of Georgia Tech during the Depression, sold X-ray equipment across Asia, then worked on radar at Raytheon during WWII. After the war, watching the aftermath of Hiroshima medical reports, he became obsessed with automating blood cell counts — a task then done by lab techs squinting through microscopes at hemocytometer grids, one cell at a time, with famously terrible reproducibility. He built the first prototype in the basement of his Chicago apartment with parts scavenged from Navy surplus. He and his brother Joseph founded Coulter Electronics; it became Beckman Coulter, still the world's dominant hematology analyzer company.

Why it's surprising. Every complete blood count (CBC) ordered anywhere on Earth — billions per year — passes cells through a Coulter aperture or an optical descendant of it. That alone is a staggering footprint for a basement invention. But the real archaeology is what came next.

• Flow cytometry (Fulwyler, Herzenberg, late 1960s) took Coulter's single-file "one particle through a constriction" geometry and swapped resistance sensing for laser scattering and fluorescence. Every FACS machine sorting immune cells today inherits Coulter's plumbing.
• Nanopore DNA sequencing — the technology inside Oxford Nanopore's MinION, the pocket-sized sequencer that mapped SARS-CoV-2 variants in the field during COVID — is literally the Coulter principle at molecular scale. A single-stranded DNA molecule is pulled through a protein pore a few nanometers wide. As each base (A, T, G, C) occupies the pore, it displaces ions and modulates the ionic current. The pulse shape reveals the base. Coulter counted cells; nanopore reads letters. Same physics.
• Impedance lab-on-chip cytometers, MEMS particle counters, Resistive Pulse Sensing for exosomes and viruses — all direct descendants, now shrunk to microfluidic silicon.

Could it be built better today? It is being built better — but the elegance of the 1949 patent is that it scales down. The same equation Coulter wrote (pulse amplitude ∝ particle volume / aperture volume) works whether the aperture is 100 microns wide, sizing red blood cells, or 1.5 nanometers wide, sizing a single nucleotide. A tinkerer without a degree wrote down a principle so scale-invariant that seventy-five years of nanotechnology has been unable to obsolete it — only miniaturize it.